2023年4月18日

2023年4月18日,中国建设银行建行Zephyrm系列B轮领导的信托公司照管,而Nio资本共同Sinpro系列是圆的。Zephyrm提出了29美元系列B资助生物制药公司Zephyrm生物技术拍摄了2亿元(2900万美元)的一系列B轮由建行领导信任,该公司周一表示。圆,由现有股东再服兵役,将帮助该公司一期和二期临床试验的多能干细胞药物候选人以及扩大其技术平台,建立生产基地,每个公司发布。然而,该公司没有透露的列表之前的支持者,在这一轮注入资本。成立于2018年,Suzhou-based Zephyrm专门从事干细胞药物的研发和制造。目前,公司的干细胞药物候选人针对呼吸道疾病、风湿性,和osteoarticular疾病在二期临床试验,每释放。之前,该公司了”几个几亿元在2019年在一个首轮私募融资轮中。该公司还建立了一个良好生产规范(GMP)设备制造干细胞药物在北京2019年5月,根据它的网站。Sinpro袋A轮Nio资本4 d成像雷达制造商Sinpro最近取得”几个几亿元在一个首轮私募融资轮中共同通过Nio资本,一家投资公司由中国电动汽车(EV)制造商Nio。北京小米智能制造业股权投资基金,基金由小米北京集成电路等领域及相关领域的投资从智能制造、新材料、人工智能,和汽车电子,也领导了。 The fund has raised around 9 billion yuan ($1.3 billion) as of March 2, with a target size of 10 billion yuan ($1.5 billion). The round, joined by Harvest Capital, also known as Jiawo Capital, will accelerate the R&D and mass production of Sinpro’s 4D imaging radars, per a company announcement on April 12. Jiawo Capital has managed over 5 billion yuan ($727.2 million) since its inception in 2015, targeting sectors including information technology, enterprise services, healthcare, energy, and new materials, according to its website. Founded in 2021, Shanghai-based Sinpro develops sensor and other related intelligent solutions for Level 3 or above self-driving vehicles. Previously, the firm disclosed that it snapped funding in an angel round shortly after the first month of inception, without divulging the investor details. Core Medical Technology bags $29m in Series C+ round Chinese artificial heart maker Core Medical Technology has bagged 200 million yuan ($29 million) in a Series C extended round led by Chinese PE firm Loyal Valley Capital, according to a company release on Monday. The round, participated by Shanghai-based alternative investment firm Greenwoods Asset, has brought the total raised capital to 1 billion yuan ($145.4 million). It comes only three months after the firm raised “several hundreds of millions yuan” in a Series C round in December 2022. Currently, the firm said it is planning to apply for an IPO, without disclosing the destination and timeline. Founded in 2016, the firm, which counts CICC Capital, GL Ventures, and CoStone Capital among its backers, engages in the research and development of high-end innovative medical devices such as left ventricular assist system for heart failure.